Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors at 3 institutions in 2 countries.
Anastasia WilliamsLaboratory of Molecular Virology, School of Systems Biology, George Mason University, Discovery Hall Room 182, 10900 University Blvd., Manassas, VA 20110, USA.
Pooja KhatkarLaboratory of Molecular Virology, School of Systems Biology, George Mason University, Discovery Hall Room 182, 10900 University Blvd., Manassas, VA 20110, USA.ORCID 0000-0003-3842-5146
Heather BranscomeLaboratory of Molecular Virology, School of Systems Biology, George Mason University, Discovery Hall Room 182, 10900 University Blvd., Manassas, VA 20110, USA.
Yuriy KimLaboratory of Molecular Virology, School of Systems Biology, George Mason University, Discovery Hall Room 182, 10900 University Blvd., Manassas, VA 20110, USA.ORCID 0000-0001-8658-6863
James EricksonLaboratory of Molecular Virology, School of Systems Biology, George Mason University, Discovery Hall Room 182, 10900 University Blvd., Manassas, VA 20110, USA.
Mohammad-Ali JenabianDepartment of Biological Sciences and CERMO-FC Research Center, University of Quebec in Montreal, Montreal, QC H2L 2C4, Canada.ORCID 0000-0003-4321-9777
Cecilia T CostiniukInfectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada.ORCID 0000-0002-4547-714X
Fatah KashanchiLaboratory of Molecular Virology, School of Systems Biology, George Mason University, Discovery Hall Room 182, 10900 University Blvd., Manassas, VA 20110, USA.ORCID 0000-0001-9681-2780
George Mason University · USMcGill University Health Centre · CAUniversité du Québec à Montréal · CA
Funding
HIV1 INHIBITION USING TAT PEPTIDE DERIVATIVESR01AI043894 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI KASHANCHI, FATAH · 1999 to 2015
$4.4M
Cell-derived extracellular vesicle mediated epigenetic silencing of HIV in the brainR01MH134389 · NIMH · GEORGE MASON UNIVERSITY · PI Fatah Kashanchi · 2023 to 2026
$2.0M
HIV neuropathogenesis related to exosomes containing HIV non-coding RNAsR01NS099029 · NINDS · GEORGE MASON UNIVERSITY · PI KASHANCHI, FATAH · 2016 to 2020
$1.9M
Effect on CBD on Exosome release from CNS infected cellsR21DA050176 · NIDA · GEORGE MASON UNIVERSITY · PI KASHANCHI, FATAH · 2020 to 2021
$447k
Effect of chromatin remodelers/modifiers on HIV-1 Tat activated transcriptionR21AI074410 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI KASHANCHI, FATAH · 2009 to 2010
$432k
A radiation-induced cellular stress activates HIV and induces killing of infected cellsR21AI127351 · NIAID · GEORGE MASON UNIVERSITY · PI KASHANCHI, FATAH · 2016 to 2017
$418k
HIV-1 TAR derived miRNA: Implications for Latency and PathogenesisR21AI078859 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI KASHANCHI, FATAH · 2009 to 2010
Currently, there is no cure for human immunodeficiency virus type 1 (HIV-1) infection. However, combined antiretroviral therapy (cART) aids in viral latency and prevents the progression of HIV-1 infection into acquired immunodeficiency syndrome (AIDS). cART has extended many lives, but people living with HIV-1 (PLWH) face lifelong ailments such as HIV-associated neurocognitive disorders (HAND) that range from asymptomatic HAND to HIV-1-associated dementia. HAND has been attributed to chronic inflammation and low-level infection within the central nervous system (CNS) caused by proinflammatory cytokines and viral products. These molecules are shuttled into the CNS within extracellular vesicles (EVs), lipid bound nanoparticles, and are released from cells as a form of intercellular communication. This study investigates the impact of cannabidiol (CBD), as a promising and potential therapeutic for HAND patients, and a similar synthetic molecule, HU308, on the EVs released from HIV-1-infected myeloid cells as well as HIV-1-infected 3D neurospheres. The data shows that both CBD and HU308 decrease non-coding and coding viral RNA (TAR and
Indexed as
cannabidiolCBDEVsextracellular vesiclesHANDHIV-1HU-308HU308human immunodeficiency virus type 1
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The Use of CBD and Its Synthetic Analog HU308 in HIV-1-Infected Myeloid Cells. · full record | OpenQuestion